Market Lifecycle Stage
The global acromegaly market is currently in the growth stage of its lifecycle, driven by significant advancements in the diagnosis and treatment of the disease. Although acromegaly remains a rare disease, its increasing prevalence and improved diagnostic capabilities have led to greater identification and awareness of the disease. This has boosted the demand for effective treatments. The approval of innovative therapies, such as long-acting somatostatin analogs and growth hormone receptor antagonists, has significantly enhanced disease management, improving patient outcomes and fueling the demand for acromegaly therapies. Furthermore, the growing focus on personalized medicine and the expansion of healthcare access in emerging markets are opening up new growth avenues. The increasing awareness among healthcare providers and patients is also contributing to the expansion of the global acromegaly market. However, challenges such as the high cost of treatments and misdiagnosis are expected to hinder the growth of the global acromegaly market.
Impact
Increasing demand for acromegaly therapies is anticipated to support the growth of the global acromegaly market during the forecast period 2025-2035.
The global acromegaly market is expected to grow at a significant rate due to advancements in diagnostic technologies, the development of innovative therapies, and increasing awareness among patients and healthcare providers.
Market Segmentation:
Segmentation 1: by Drug Class
Somatostatin Analogues (SSAs)
Growth Hormone Receptor Antagonists (GHRAs)
Others
Segmentation 2: by Region
North America
Europe
Asia-Pacific
Latin America
Rest-of-the-World
North America is expected to dominate the global acromegaly market during the forecast period due to its advanced healthcare infrastructure, high prevalence, and increased awareness of the disease. The region also benefits from regulatory advantages and a strong pharmaceutical presence, which accelerates the availability of effective treatments and drives the growth of the global acromegaly market.
Recent Developments in the Global Acromegaly Market
Regulatory Activities: In March 2025, Crinetics Pharmaceuticals announced the European Medicines Agency (EMA) validation of the Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in the treatment of acromegaly.
Product Launches: In October 2024, Teva Pharmaceutical Industries Ltd. announced the launch of the first and only generic version of Sandostatin® LAR Depot in the U.S.
Regulatory Activities: In May 2024, Cipla received U.S. FDA approval to market Lanreotide injection in the U.S.
Demand – Drivers and Limitations
The following are the drivers for the global acromegaly market:
Rising Prevalence of Acromegaly
Continuous Advancements in Treatment Options
Growing Healthcare Investment in Rare Diseases
The global acromegaly market is expected to face some limitations too, due to the following challenges:
High Treatment Costs
Limited Awareness in the Underdeveloped Regions and Misdiagnosis of the Disease
How Can This Report Add Value to an Organization?
Product/Innovation Strategy:Product launches and innovations in the global acromegaly market are focused on advancing treatment options to improve patient care. These innovations aim to enhance the efficacy of therapies and streamline the detection and management of the disease. Key players in the market, such as Merck, and Enanta Pharmaceuticals, have been involved in the development of therapies for acromegaly.
Competitive Strategy:Enterprises led by market leaders in the global acromegaly market are continuously working on updating their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players in the global acromegaly market has been conducted, providing insights into how these companies compare in terms of product offerings, market share, and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and by analyzing company coverage, product portfolio, and market penetration.
Some of the prominent names established in this market are:
Novartis AG
Sun Pharmaceutical Industries Ltd
Ipsen Pharma
Chiasma, Inc.
Peptron, Inc.
Crinetics Pharmaceuticals Inc.
Camurus
Ionis Pharmaceuticals, Inc.
Dauntless Pharmaceuticals
Immunwork, Inc.
Cipla
Teva Pharmaceutical Industries Ltd.
*PDF email from publisher allows for 1-3 users, with permission to print*
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- Executive Summary
- Scope of Study
- 1. Global Acromegaly Market Overview
- 1.1 Industry Outlook
- 1.1.1 Introduction
- 1.1.2 Market Overview and Ecosystem
- 1.1.3 Epidemiological Analysis of Acromegaly
- 1.1.3.1 By Region
- 1.1.3.1.1 U.S.
- 1.1.3.1.2 EU5
- 1.1.3.1.3 Rest-of-the-World
- 1.1.3.2 By Age Group
- 1.1.4 Key Trends
- 1.1.5 Clinical Trials
- 1.1.5.1 By Phase
- 1.1.6 Regulatory Landscape / Compliances
- 1.1.6.1 Legal Requirement and Framework in U.S.
- 1.1.6.2 Legal Requirement and Framework in E.U.
- 1.1.6.3 Legal Requirement and Framework in Asia-Pacific
- 1.1.6.4 Legal Requirement and Framework in Rest-of-the-World
- 1.1.7 Pricing Analysis
- 1.2 Market Dynamics
- 1.2.1 Market Drivers
- 1.2.1.1 Impact Analysis
- 1.2.2 Market Restraints
- 1.2.2.1 Impact Analysis
- 1.2.3 Market Opportunities
- 2. Global Acromegaly Market (By Drug Class), $Million, 2023-2035
- 2.1 Overview
- 2.2 Somatostatin Analogues (SSAs)
- 2.3 Growth Hormone Receptor Antagonists (GHRAs)
- 2.4 Others
- 3. Global Acromegaly Market (By Region), $Million, 2023-2035
- 3.1 North America
- 3.1.1 Market Dynamics
- 3.1.1.1 Impact Analysis
- 3.1.2 Market Sizing and Forecast
- 3.1.2.1 North America Acromegaly Market (by Drug Class)
- 3.1.2.2 North America Acromegaly Market (by Country)
- 3.1.2.2.1 U.S.
- 3.1.2.2.2 Canada
- 3.2 Europe
- 3.2.1 Market Dynamics
- 3.2.1.1 Impact Analysis
- 3.2.2 Market Sizing and Forecast
- 3.2.2.1 Europe Acromegaly Market (by Drug Class)
- 3.2.2.2 Europe Acromegaly Market (by Country)
- 3.2.2.2.1 U.K.
- 3.2.2.2.2 Germany
- 3.2.2.2.3 France
- 3.2.2.2.4 Italy
- 3.2.2.2.5 Spain
- 3.2.2.2.6 Rest-of-Europe
- 3.3 Asia-Pacific
- 3.3.1 Market Dynamics
- 3.3.1.1 Impact Analysis
- 3.3.2 Market Sizing and Forecast
- 3.3.2.1 Asia-Pacific Acromegaly Market (by Drug Class)
- 3.3.2.2 Asia-Pacific Acromegaly Market (by Country)
- 3.3.2.2.1 Japan
- 3.3.2.2.2 China
- 3.3.2.2.3 India
- 3.3.2.2.4 Australia
- 3.3.2.2.5 South Korea
- 3.3.2.2.6 Rest-of-Asia-Pacific
- 3.4 Latin America
- 3.4.1 Market Dynamics
- 3.4.1.1 Impact Analysis
- 3.4.2 Market Sizing and Forecast
- 3.4.2.1 Latin America Acromegaly Market (by Drug Class)
- 3.4.2.2 Latin America Acromegaly Market (by Country)
- 3.4.2.2.1 Brazil
- 3.4.2.2.2 Mexico
- 3.4.2.2.3 Rest-of-Latin America
- 3.5 Rest-of-the-World
- 3.5.1 Market Dynamics
- 3.5.2 Market Size and Forecast
- 3.5.2.1 Rest-of-the-World Acromegaly Market (by Drug Class)
- 4. Global Acromegaly Market - Competitive Benchmarking and Company Profiles
- 4.1 Competitive Benchmarking
- 4.2 Competitive Landscape
- 4.2.1 Key Strategies and Developments by Company
- 4.2.1.1 Funding Activities
- 4.2.1.2 Mergers and Acquisitions
- 4.2.1.3 Regulatory Approvals
- 4.2.1.4 Partnerships, Collaborations and Business Expansions
- 4.2.2 Key Developments Analysis
- 4.3 Company Profiles
- 4.3.1 Novartis AG
- 4.3.1.1 Company Overview
- 4.3.1.2 Product Portfolio
- 4.3.1.3 Target Customers/End Users
- 4.3.1.4 Analyst View
- 4.3.2 Sun Pharmaceutical Industries Ltd
- 4.3.2.1 Company Overview
- 4.3.2.2 Product Portfolio
- 4.3.2.3 Target Customers/End Users
- 4.3.2.4 Analyst View
- 4.3.3 Ipsen Pharma
- 4.3.3.1 Company Overview
- 4.3.3.2 Product Portfolio
- 4.3.3.3 Target Customers/End Users
- 4.3.3.4 Analyst View
- 4.3.4 Chiasma, Inc.
- 4.3.4.1 Company Overview
- 4.3.4.2 Product Portfolio
- 4.3.4.3 Target Customers/End Users
- 4.3.4.4 Analyst View
- 4.3.5 Peptron, Inc.
- 4.3.5.1 Company Overview
- 4.3.5.2 Product Portfolio
- 4.3.5.3 Target Customers/End Users
- 4.3.5.4 Analyst View
- 4.3.6 Crinetics Pharmaceuticals Inc.
- 4.3.6.1 Company Overview
- 4.3.6.2 Product Portfolio
- 4.3.6.3 Target Customers/End Users
- 4.3.6.4 Analyst View
- 4.3.7 Camurus
- 4.3.7.1 Company Overview
- 4.3.7.2 Product Portfolio
- 4.3.7.3 Target Customers/End Users
- 4.3.7.4 Analyst View
- 4.3.8 Ionis Pharmaceuticals, Inc.
- 4.3.8.1 Company Overview
- 4.3.8.2 Product Portfolio
- 4.3.8.3 Target Customers/End Users
- 4.3.8.4 Analyst View
- 4.3.9 Dauntless Pharmaceuticals
- 4.3.9.1 Company Overview
- 4.3.9.2 Product Portfolio
- 4.3.9.3 Target Customers/End Users
- 4.3.9.4 Analyst View
- 4.3.10 Immunwork, Inc.
- 4.3.10.1 Company Overview
- 4.3.10.2 Product Portfolio
- 4.3.10.3 Target Customers/End Users
- 4.3.10.4 Analyst View
- 4.3.11 Cipla
- 4.3.11.1 Company Overview
- 4.3.11.2 Product Portfolio
- 4.3.11.3 Target Customers/End Users
- 4.3.11.4 Analyst View
- 4.3.12 Teva Pharmaceutical Industries Ltd.
- 4.3.12.1 Company Overview
- 4.3.12.2 Product Portfolio
- 4.3.12.3 Target Customers/End Users
- 4.3.12.4 Analyst View
- 5. Research Methodology
- List of Figures
- Figure: Global Acromegaly Market, Market Overview
- Figure: Global Acromegaly Market, Epidemiological Analysis, U.S.
- Figure: Global Acromegaly Market, Epidemiological Analysis, EU5
- Figure: Global Acromegaly Market Coverage
- Figure: Global Acromegaly Market Key Trends, Impact Analysis, 2023-2035
- Figure: Global Acromegaly Market, Competitive Landscape, January 2022-April 2025
- List of Tables
- Table: Global Acromegaly Market, Regulatory Scenario
- Table: Global Acromegaly Market Dynamics, Impact Analysis
- Table: Global Acromegaly Market (by Drug Class), $Million, 2023-2035
- Table: Global Acromegaly Market (by Region), $Million, 2023-2035
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook